Abstract: Pro-benefit-agent compounds having heterocyclic moieties that include a benefit agent fragment derived from benefit agents, such as perfume raw materials, that include an aldehyde moiety or a ketone moiety. The pro-benefit-agent compounds may be derived from modified amino acids. Related treatment compositions, premix compositions, precursor compounds, and methods of making and using such materials and compositions.
Type:
Grant
Filed:
May 24, 2022
Date of Patent:
July 16, 2024
Assignee:
The Procter & Gamble Company
Inventors:
Sean N. Natoli, Rajan Keshav Panandiker, Gregory Scot Miracle, Jenna Marie Hoover
Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
Type:
Grant
Filed:
June 1, 2021
Date of Patent:
July 16, 2024
Assignee:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
Abstract: Provided are substituted 8-methylquinazolin-4(3H)-one compounds useful as PARP inhibitors for the treatment of cancer and asthma, as well as pharmaceutical compositions comprising them and methods for their synthesis.
Abstract: The present disclosure relates to novel processes for the preparation of compounds of Formula I. Some of these compounds are useful as stimulators of soluble guanylate cyclase (sGC). Others are useful intermediates towards the preparation of said stimulators. These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of Formula I in high purity and yields. The present invention has the additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides novel intermediates useful in the preparation of said compounds.
Type:
Grant
Filed:
April 28, 2023
Date of Patent:
July 9, 2024
Assignee:
Cyclerion Therapeutics, Inc.
Inventors:
Debra Jane Wallace, Fenger Zhou, Yuguang Wang, Takashi Nakai, Vishnu Vardhan Reddy Karnati, Wayne C. Schairer, William Kissel, Song Xue, Ahmad Hashash
Abstract: The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
Type:
Grant
Filed:
June 14, 2019
Date of Patent:
July 9, 2024
Assignee:
University of Florida Research Foundation, Incorporated
Abstract: The present disclosure relates, in general, to improved processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)-benzamide, particularly large-scale processes for manufacturing 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide and intermediates used in such processes.
Type:
Grant
Filed:
August 28, 2019
Date of Patent:
July 2, 2024
Assignee:
ACERTA PHARMA B.V.
Inventors:
Paul Allen Bethel, Lai Chun Chan, Katie Grace Cooper, Robert John Cox, Michael David Golden, Shaun Alan Hughes, Lucinda Victoria Jackson, Kirsty Jane Millard, Andrew John Phillips, Alexander James Telford, Jerry Evarts, Michael Joseph Lawler, Remy E. J. N. Litjens, Peter Johannes Servaas Savio Van Eijk, Mathilda Maria Henrica Verstappen, Frank L. M. Vos, Eric Jurriƫn Zijp, Qiu Junying, Rustam Ferdinand Garrey, David Allen Short, Angang Wang
Abstract: A pharmaceutical composition containing forskolin and retinoic acid as active ingredients which is suitable for preventing or treating sensorineural hearing loss is disclosed. A pharmaceutical composition containing forskolin and retinoic acid as active ingredients has an excellent effect of preventing, alleviating or treating hearing loss caused by ototoxic drugs during anticancer treatment, and thus is useful as a pharmaceutical composite preparation capable of reducing side effects of anticancer drugs and, additionally, as an agent for preventing or treating sensorineural hearing loss.
Type:
Grant
Filed:
August 6, 2019
Date of Patent:
June 18, 2024
Assignee:
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Abstract: A compound 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.
Type:
Grant
Filed:
December 26, 2023
Date of Patent:
June 11, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer, Sahar M. Mohamed, Mohammad Mahboob Alam
Abstract: The present invention relates to processes for preparing a Compound (1): or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.
Type:
Grant
Filed:
January 10, 2023
Date of Patent:
June 11, 2024
Assignee:
Enanta Pharmaceuticals, Inc.
Inventors:
Kaicheng Zhu, Tao Wang, Jiajun Zhang, Hui Cao, Ruichao Shen, Guoqiang Wang, George G. Wu, Yat Sun Or
Abstract: Pharmaceutical intermediates and methods for efficiently preparing muscimol mono-BOC and derivatives thereof in the synthesis of muscimol and congeners and derivatives thereof.
Abstract: Thiazole tethered organoselenide compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The thiazole tethered organoselenide compounds are identified as being capable of inhibiting 5-lipoxygenase (5-LO).
Abstract: Pharmaceutical combinations of LTV-17 (I), a lactivicin derivative, and ?-lactamase inhibitors are provided, wherein the combinations comprise antibacterial agents suitable for use in the treatment or prevention of bacterial infections.
Type:
Grant
Filed:
November 10, 2022
Date of Patent:
June 4, 2024
Assignee:
FEDORA PHARMACEUTICALS INC.
Inventors:
Sameeh M. Salama, Samarendra N. Maiti, Renata Jankowska
Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
Type:
Grant
Filed:
September 27, 2022
Date of Patent:
May 28, 2024
Assignee:
Rigel Pharmaceuticals, Inc.
Inventors:
Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
Abstract: A 4,4?-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)Cl(PiPr3)2 moieties, its synthesis, and its use as an catalyst in organic processes.
Type:
Grant
Filed:
November 14, 2023
Date of Patent:
May 21, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Obadah S. Abdel-Rahman, Mohamed Shaker S. Adam
Abstract: A 4,4?-divinylazobenzene-bridged diruthenium complex bearing two Ru(Co)Cl(PiPr3)2 moieties, its synthesis, and its use as an catalyst in organic processes.
Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.